Novo Nordisk and Aspect Biosystems collaborate to create disease-modifying treatments for diabetes and obesity

(IN BRIEF) Novo Nordisk has announced a collaboration with Aspect Biosystems to develop bioprinted tissue therapeutics for diabetes and obesity treatment. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s expertise in stem cell differentiation and cell therapy development … Read the full press release →